急性淋巴细胞白血病中枢神经系统受累:发病机制与靶向治疗
中枢神经系统(CNS)受累是急性淋巴细胞白血病(ALL)的不良并发症,与患者预后差相关。该综述整合了ALL细胞CNS浸润与持续存在的最新研究进展,聚焦于使白血病细胞在该部位存活及治疗耐药的信号与代谢框架,并评估了新型靶向治疗策略。
要点
- ALL的CNS受累与不良预后相关,诊断和治疗面临挑战。
- CNS微环境通过ALL细胞黏附和代谢重编程促进存活与耐药。
- 靶向CNS微环境相关信号与代谢通路是潜在治疗方向。
核心结论
- 对ALL细胞CNS浸润与持续存在机制的理解显著提升,揭示了具有治疗潜力的通路。
研究设计与样本
- 综述整合近年关于ALL中枢神经系统浸润与持续存在的研究进展。
主要发现
- ALL细胞通过多种机制浸润CNS,近期研究聚焦其在CNS持续存在的机制。
- CNS微环境通过ALL细胞黏附和代谢重编程促进白血病细胞存活和治疗耐药。
临床怎么用
- 关注CNS微环境介导的存活与耐药通路,探索靶向治疗以提高CNS导向治疗疗效。
局限性
- 对CNS疾病发病机制理解不完整,是开发新型治疗和生物标志物的障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Involvement of the central nervous system (CNS) is an adverse complication of acute lymphoblastic leukemia (ALL) associated with poor patient outcomes. Clinical challenges in the diagnosis and treatment of ALL in the CNS arise from an incomplete understanding of CNS disease pathogenesis, a significant barrier to developing novel therapeutics and biomarkers to address these challenges. A concerted research effort over recent years has significantly improved our understanding of CNS disease pathogenesis in ALL. Numerous CNS-infiltrating mechanisms by ALL cells have been uncovered, so recent research focuses on how ALL persists in this site. The role of the CNS microenvironment in the survival and therapy resistance of ALL is emerging, driven by ALL cell adhesion and metabolic reprogramming, revealing pathways with therapeutic potential. Here, we integrate recent advances in CNS infiltration and persistence in ALL, focusing on the signaling and metabolic frameworks that enable leukemic survival and therapy resistance once established in this site. We also evaluate novel therapeutic avenues and emerging targeted therapies that could enhance the efficacy of CNS-directed therapy in ALL.
引用
- Quinlan L, Yeung D, Heatley S, et al. Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy. Leukemia. 2026. PMID: 42469478. doi:10.1038/s41375-026-03060-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。